Gene signature | RFi | OS |
---|
Univariable | Multivariablea | Univariable | Multivariablea |
---|
HR (95% CI) | p (q) | HR (95% CI) | p (q) | HR (95% CI) | p (q) | HR (95% CI) | p (q) |
---|
AR | 1.14 (0.76–1.72) | 0.52 (0.87) | 1.20 (0.80–1.81) | 0.37 (0.62) | 1.38 (0.88–2.16) | 0.16 (0.20) | 1.48 (0.95–2.30) | 0.082 (0.10) |
ESR1 | 1.38 (0.90–2.11) | 0.15 (0.37) | 1.27 (0.80–2.00) | 0.31 (0.62) | 1.57 (0.98–2.53) | 0.062 (0.16) | 1.61 (0.97–2.66) | 0.066 (0.10) |
FOXA1 | 2.24 (1.45–3.45) | 0.00027 (0.0013) | 2.00 (1.27–3.14) | 0.0027 (0.014) | 2.25 (1.42–3.56) | 0.00058 (0.0029) | 2.16 (1.32–3.52) | 0.0021 (0.011) |
Mast cells | 0.97 (0.64–1.47) | 0.89 (0.89) | 1.03 (0.68–1.56) | 0.88 (0.92) | 1.00 (0.64–1.55) | 0.98 (0.98) | 1.04 (0.66–1.62) | 0.88 (0.88) |
PGR | 0.97 (0.65–1.44) | 0.88 (0.89) | 1.02 (0.68–1.55) | 0.92 (0.92) | 1.40 (0.92–2.12) | 0.12 (0.19) | 1.54 (0.99–2.39) | 0.054 (0.10) |
- The HR:s presented are for the multiplicative interaction term between each gene signature (unit 1 SD) and treatment (binary) in models including also the main effects for gene signature and treatment. Hence, an interaction HR of 1.00 corresponds to an effect of treatment which does not vary with expression of the gene signature, while interaction HR ≠ 1.00 suggests that an increase in the gene signature score associates with tamoxifen treatment being less effective or more effective in preventing the event of interest, for interaction HR > 1.00 and HR < 1.00 respectively
- Interaction terms for the ER+/HER2− cohort of tamoxifen treatment and selected gene signatures as continuous scores, estimated by Cox proportional hazards regression
- aAdjusted for PAM50 subtype, node status, NHG, age, and tumor size
- CI confidence interval, ER estrogen receptor, HER2 human epidermal growth factor receptor 2, HR hazard ratio, OS overall survival, RFi recurrence-free interval, SD standard deviation